PROTAB
ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
PROTAB
Industry:
Biopharma Biotechnology Health Care Life Science Pharmaceutical
Founded:
2005-01-01
Address:
Jerusalem, Yerushalayim, Israel
Country:
Israel
Website Url:
http://www.hbl.co.il
Total Employee:
1+
Status:
Active
Total Funding:
4 M USD
Technology used in webpage:
Google Analytics Google Maps Google Analytics Classic
Similar Organizations
KYAN Therapeutics
KYAN Therapeutics is a clinical-stage AI company leveraging its proprietary technology platforms to transform the way patients are treated.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Current Employees Featured
Founder
Investors List
Clal Biotechnology Industries
Clal Biotechnology Industries investment in Series A - ProtAb
Pontifax
Pontifax investment in Series A - ProtAb
HBL Hadasit Bio Holdings
HBL Hadasit Bio Holdings investment in Series A - ProtAb
Official Site Inspections
http://www.hbl.co.il
- Host name: 104.21.67.149
- IP address: 104.21.67.149
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
